Mesirow Financial Investment Management, Inc. Lineage Cell Therapeutics, Inc. Transaction History
Mesirow Financial Investment Management, Inc.
- $4.79 Billion
- Q4 2024
A detailed history of Mesirow Financial Investment Management, Inc. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Mesirow Financial Investment Management, Inc. holds 20,001 shares of LCTX stock, worth $10,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,001Holding current value
$10,000% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LCTX
# of Institutions
135Shares Held
106MCall Options Held
22.1KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$20.8 Million1.65% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$4.78 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.63MShares$4.32 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY7.24MShares$3.62 Million0.12% of portfolio
-
Defender Capital, Llc.5.96MShares$2.98 Million1.17% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $84.9M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...